2 min read

Krishna Institute of Medical Sciences Moat Analysis: Score & Risks

Moat Note · First-pass

Krishna Institute of Medical Sciences Ltd.

A first-pass moat teardown of Krishna Institute of Medical Sciences Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

Moat & Margin16 Aug 2026 First-pass · ~3 min
4.28 / 10
NARROWProcess/Data-led

First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Krishna Institute of Medical Sciences Ltd. scores 4.28 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown

Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.

D3Cost Advantage4.8
M · Mechanism Verified verbatim

“total revenue on standalone basis decreased by 1.03% to Rs. 11,555.20 million in FY23 compared to Rs. 11,675.50 million in the previous year”

Krishna Institute of Medical Sciences Ltd. · Annual Report · p.22
D6Efficient Scale4.8
M · Mechanism Verified verbatim

“EBITDA margin stood at 20.4% versus 25.9% in Q3 FY 25 and 21.6% in Q2 FY 26”

Krishna Institute of Medical Sciences Ltd. · Earnings Call · p.3
D1Network Effects4.7
M · Mechanism Verified verbatim

“These new assets are not just additions to our network; they are gateways to serving millions of new patients and establishing KIMS as a pan-Indian healthcare provider.”

Krishna Institute of Medical Sciences Ltd. · Annual Report · p.12
D4Price Discretion4.7
M · Mechanism Verified verbatim

“Mr. Vikas Maheshwari Chief Financial Officer (Resigned w.e.f. 01.06.2023)”

Krishna Institute of Medical Sciences Ltd. · Annual Report · p.4
D5Intangible Assets4.7
O · Outcome Verified verbatim

“I just have 1 more additional question. So just want to understand what is plan to reduce promoter pledge like right now, there is notable pledging of promoter stake”

Krishna Institute of Medical Sciences Ltd. · Earnings Call · p.12
1 quote extracted here — not one mechanism-class. The evidence is outcome-only.
D2Switching Costs4.5
No verified filing quote surfaced for this dimension in the first-pass evidence sweep.
D7Counter-PositioningExcluded
Excluded for this archetype.
D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate

The barrier gate — first-pass

Replication — can a rival copy it?5.0
How hard it is for a rival to copy the edge (first-pass estimate).
Bypass — can a rival route around it?5.0
How easily a rival can route around the edge (first-pass estimate).

Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.

What would change our mind
  1. Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.

  2. The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.

  3. Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.